Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
63 hedge funds and large institutions have $408M invested in Mirati Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 13 closing their positions.
528% more call options, than puts
Call options by funds: $2.3M | Put options by funds: $366K
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
108% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 13
100% more capital invested
Capital invested by funds: $204M → $408M (+$204M)
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
29% more funds holding
Funds holding: 49 → 63 (+14)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$14.6M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$10.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$10.6M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$9.31M |
| 5 |
Jennison Associates
New York
|
+$7.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.21M |
| 2 |
Morgan Stanley
New York
|
-$2.33M |
| 3 |
RA
Royce & Associates
New York
|
-$2.02M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$1.93M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.53M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
BNP Paribas Financial Markets
Paris,
France
| – | -$23 | -2 | Closed |
|
MRTX Hedge Fund Activity: Q4 2017 in Review
63 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q4 2017, worth a combined $408M — up 100% from $204M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new MRTX positions and 13 closed out — a net gain of 14 holders — while 20 added to existing stakes and 12 trimmed.
The largest buyer was Putnam Investments, opening a new position worth an estimated $14.6M. The largest seller was Millennium Management, exiting entirely with an estimated $5.21M sold.
- 63 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q4 2017, up from 49 in Q3 2017.
- Funds reported $408M of Mirati Therapeutics, Inc. Common Stock stock for Q4 2017, up 100% quarter-over-quarter.
- 27 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q4 2017 and 13 closed out, a net change of +14 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q4 2017 was Putnam Investments, an estimated $14.6M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q4 2017 was Millennium Management, an estimated $5.21M sold.
Based on aggregated 13F filings for Q4 2017.